Dear Shareholders and readers
I am pleased to report significant clinical, strategic and financial progress for this quarter. In November we reported that 11 out of 12 patients treated with intralymphatic Diamyd® in the DIAGNODE-1 trial are in partial remission about 18 months after diagnosis of type 1 diabetes. This is notable as partial remission, defined as the patient having a well-controlled blood sugar level and a low requirement for external insulin, is seen in patients that have had the disease for more than a year....